PGA MANA MEDICAL RESEARCH

Advanced Medical Research , Pioneering Translational Science from Bench to Bedside

Our research division is a multidisciplinary powerhouse, integrating pharmacology, molecular pathology, stem cell biology, immunology, and mRNA-based therapeutics to address the most pressing challenges in modern medicine. pg
Pharmacology & Drug Development , Precision in Therapeutics
We specialize in the comprehensive evaluation of pharmaceutical agents across all phases of translational research:p
 Drug Discovery & High-Throughput Screening  Identification of novel small molecules, biologics, and nucleic acid-based therapeutics through advanced in silico modeling and phenotypic screening platforms.p
 Pharmacokinetics & Pharmacodynamics (PK/PD)  Rigorous characterization of drug absorption, distribution, metabolism, and excretion (ADME), alongside dose-response relationships and efficacy endpoints in preclinical models and early-stage clinical
trials.p
 Receptor Pharmacology & Signal Transduction Detailed investigation of G-protein coupled receptors (GPCRs), tyrosine kinase
receptors (RTKs), nuclear hormone receptors, and immune checkpoint receptors (PD-1, CTLA-4, LAG-3) . We map ligand-receptor interactions, downstream signaling cascades (MAPK, PI3K/AKT, JAK/STAT, NF-κB), and mechanisms of receptor desensitization, internalization, and cross-talk critical for understanding drug action, resistance, and toxicity.p
 Ion Channels & Transporter Pharmacology  Studying voltage-gated and ligand-gated ion channels, ATP-binding cassette (ABC) transporters, and solute carrier (SLC) families as therapeutic targets in neurological, cardiovascular, and metabolic diseases.p
Personalized Pharmacogenomics  Correlating genetic polymorphisms with drug response variability, enabling genotype-guided dosing strategies and minimizing adverse drug reactions.p
 Immunopharmacology & Cytokine Modulation  Evaluating the effects of pharmacological agents on interleukin networks (IL-2, IL-6, IL-10, IL-17, IL-23), tumor necrosis factor (TNF-α), and interferon (IFN) pathways. We assess how drugs modulate immune cell polarization, inflammation resolution, and autoimmunity.p
 Nanopharmacology & Targeted Delivery  Designing lipid nanoparticles, polymeric micelles, and antibody-drug conjugates (ADCs) for site-specific drug release, enhanced bioavailability, and reduced off-target toxicity.p
 Toxicology & Safety Pharmacology  Comprehensive preclinical safety assessment, including organ-specific toxicity, genotoxicity, immunotoxicity, and reproductive toxicology, complying with ICH and OECD guidelines.p
Pathology The Cornerstone of Precision Diagnosis
Our pathology division operates at the intersection of traditional morphological assessment and cutting-edge molecular diagnostics, providing a deep understanding of disease mechanisms and therapeutic stratification:p
 Histopathology & Morphological Analysis  High-resolution evaluation of tissue architecture using routine and special staining, immunohistochemistry (IHC), and electron microscopy. We identify cellular atypia, architectural distortion, stromal infiltration, and vascular invasion across all major organ systems.p
Molecular Pathology & Genomic Profiling Comprehensive analysis of somatic mutations, copy number variations, chromosomal translocations, and microsatellite instability (MSI) using next-generation sequencing (NGS), PCR-based assays, and fluorescence in situ hybridization (FISH). We correlate molecular signatures with clinical outcomes and drug sensitivity.p
Immunopathology & Host Inflammatory Response  Characterization of tumor-infiltrating lymphocytes (TILs), tertiary lymphoid structures, and the spectrum of immune cell populations (CD4+, CD8+, Tregs, macrophages, dendritic cells) within the tumor microenvironment. Assessment of PD-L1 expression and immune exhaustion markers guides patient selection for checkpoint inhibitor therapy.p
 Oncopathology & Tumor Heterogeneity – Deciphering intratumoral and intertumoral heterogeneity, clonal evolution, and mechanisms of acquired resistance to chemotherapy, targeted therapy, and immunotherapy. We employ single-cell sequencing and spatial transcriptomics to map the dynamic interplay between neoplastic cells and their microenvironment.p
 Inflammatory & Degenerative Pathology  Investigating the histopathological hallmarks of autoimmune diseases (rheumatoid arthritis, inflammatory bowel disease, lupus), neurodegenerative disorders (Alzheimer's, Parkinson's, multiple sclerosis), and metabolic pathologies (non-alcoholic steatohepatitis, diabetic nephropathy).p
 Digital Pathology & Artificial Intelligence  Leveraging whole-slide imaging and AI-driven algorithms for quantitative morphometry, biomarker quantification, and predictive analytics enhancing diagnostic accuracy and reproducibility.p

Stem Cell Biology & Regenerative Medicine
· Characterization of embryonic, induced pluripotent (iPSCs), and adult mesenchymal (MSCs) stem cells.
· Differentiation protocols toward neuronal, cardiomyocyte, hepatocyte, and pancreatic beta-cell lineages.
· Paracrine mechanisms, exosome biology, and immunomodulatory properties of stem cells.
· Scaffold-based and scaffold-free tissue engineering for organ repair and transplantation.

Immunology & Cytokine Networks
· Innate and adaptive immune signaling, pattern recognition receptors (TLRs, NLRs), and complement cascade.
· Interleukin biology: structural biology, receptor complexes, JAK/STAT signaling, and downstream transcriptional programming.
· Mechanisms of immune tolerance, checkpoint regulation, and autoinflammatory syndromes.
· Development of monoclonal antibodies, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies.

mRNA Therapeutics & Gene Modulation
· mRNA vaccine design: structure optimization, 5′ capping, polyadenylation, and nucleotide modification.
· Lipid nanoparticle (LNP) formulation and tissue-specific targeting.
· In vivo and ex vivo gene editing using CRISPR-Cas9, base editors, and prime editors.
· Non-viral delivery systems and theranostic applications.

Collaborative International Framework
We actively partner with leading academic medical centers, CROs, and regulatory authorities across Europe, North America, and Asia. Our research outputs spanning high-impact peer-reviewed publications, patent filings, and clinical trial designs reflect the highest standards of scientific integrity and methodological rigor.p

This is not mere research. This is the systematic pursuit of medical breakthroughs where pharmacology meets pathology, where immunology informs therapy, and where discovery is translated into life-saving interventions. We are the academic and clinical bridge between Iran's scientific talent and the global medical frontier.p

About Medical RESEARCH

Beyond Research – Strategic Investment in Medical Innovation

Our commitment to advancing medical science extends far beyond the laboratory and the clinic. We are not merely observers or facilitators of scientific progress we are active investors in the future of healthcare.pg

Through our dedicated investment arm, we identify, fund, and nurture transformative projects across the translational research spectrum:pg

· Early‑stage drug discovery  Supporting novel pharmacological targets from hit identification through lead optimization.pg
· Biotechnology startups Providing seed funding, infrastructure, and mentorship to emerging companies in gene therapy, immuno‑oncology, and regenerative medicine.pg
· Clinical trial infrastructure  Investing in state‑of‑the‑art facilities, data management platforms, and patient recruitment networks to accelerate the evaluation of new therapeutics.pg
· Intellectual property development   Securing and commercializing patents arising from our collaborative research, ensuring that scientific breakthroughs reach the market and, ultimately, the patient.pg
· Academic‑industry partnerships  Bridging the gap between university laboratories and pharmaceutical enterprises through strategic co‑investment and knowledge transfer agreements.pg
· International research consortiums  Co‑financing multi‑center studies that address global health priorities, from emerging infectious diseases to non‑communicable epidemics.pg

We invest not only capital but also scientific expertise, regulatory intelligence, and global networks—transforming promising ideas into clinically meaningful products and platforms. Our portfolio is guided by a dual mandate: scientific excellence and sustainable economic return, ensuring that every project we support has the potential to improve human health while creating lasting value for our partners and stakeholders.pg

We are not just researchers. We are architects of the medical future and we fund the blueprints.pg
​​​​​​​